1.Stahl, SM. Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.Google Scholar

2.Stahl, SM. Dopamine system stabilizers, aripiprazoie, and the next generation of antipsychotics, part 1: “Goldilocks” actions at dopamine receptors. J Clin Psychiatry. 2001;62:841–842.Google Scholar

3.Stahl, SM. Dopamine system stabilizers, aripiprazoie, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001;62:923–924.Google Scholar

4.Citrome, L. A review of aripiprazoie in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2:427–443.Google Scholar

5.Bristol-Myers, Squibb. CN13B-003: a multicenter, double blind, randomized comparative study of aripiprazoie and olanzapine in the treatment of patients with acute schizophrenia (online). 2005. URL:http://ctr.bms.com/ctd.CN138003.pdf. Accessed January 16, 2006.Google Scholar

6. Results of Phase III study of bifeprunox in subjects with acute exacerbation of schizophrenia [press release]. Marietta, Ga: Solvay Pharmaceuticals; October 2007.Google Scholar

7. Forest Laboratories and Gedeon Richter. Results of Phase IIB study for RGH188 as a treatment for schizophrenia [press release/. November, 2007.Google Scholar

8.Lawler, CP, Priouleau, C, Lewis, MM, et al.Interactions of the novel antipsychotic aripiprazoie (OPC14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1939;20:612–627.Google Scholar

9.Mamo, D, Graff, A, Mizrahi, R, Shammi, CM, Romeyer, F, Kapur, S. Differential effects of aripiprazoie on D2, 5HT2 and 5HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164:1411–1417.Google Scholar

10.Thase, ME, Marcus, RN, Hennicken, D, McQuade, RD, Carson, WH, Berman, RM. Efficacy and safety of aripiprazoie as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (Study CN138-163). Paper presented at: Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18-20, 2006; Toronto, Canada.Google Scholar

11.Berman, RM, Marcus, RN, Swanink, R, et al.Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843–853.CrossRefGoogle ScholarPubMed

12.Marcus, RN, Owen, R, Swanink, R, McQuade, RD, Carson, WH, Iwamoto, T. Two studies to evaluate the safety and efficacy of aripiprazole monotherapy in outpatients with bipolar I disorder with a major depressive episode without psychotic features. Paper presented at: Annual Meeting of the American Psychiatric Association. May 19-24, 2007; San Diego, Calif.Google Scholar

13.Thase, ME, Jonas, A, Khan, A, Bowden, CL, et al.Aripiprazoie monotherapy in nonpsychotic bipolar I depression. J Clin Psychopharmacol. 2008;28:13–20.Google Scholar

14.Kiss, B, Schmidt, E, Horvath, A, et al. RGH188, a D3/D2 dopamine receptor antagonist/partial agonist antipsychotic candidate: neurochemical profile. Abstract presented at: Dopamine 50 years. May 30-June 2, 2007; Goteborg, Sweden.Google Scholar

15.Adham, N, Gyertyan, IKiss, B, et al. Antidepressant-like activity of RGH188, a potential antipsychotic with D3/D2 antagonist/partial agonist properties in a chronic mild stress-induced anhedonia model. Abstract presented at: Annual Meeting of the Society of Neuroscience. November 3-7, 2007; San Diego, Calif.Google Scholar

16.Pasztor Meszaros, G, Kapas, M, Borsos, M, et al. Pharmacokinetics of RGH188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Abstract presented at: Annual Meeting of the European College of Neuropsychopharmacology. October 13-17, 2007; Vienna, Austria.Google Scholar

17.Shim, JC, Shin, JG, Kelly, DL, et al.Adjunctive treatment with a dopamine partial agonist, aripiprazoie, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404–1410.CrossRefGoogle ScholarPubMed

18.Chen, CH, Huang, MC, Lu, ML. Aripiprazoie improves metabolic adversity in olanzapine-treated schizophrenic patients. J Clin Psychopharmacol. 2007;27:516–517.Google Scholar